We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi (SNY) Stock Moves -0.61%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Sanofi (SNY - Free Report) closed at $47.57, marking a -0.61% move from the previous day. This move was narrower than the S&P 500's daily loss of 0.7%. Meanwhile, the Dow lost 0.87%, and the Nasdaq, a tech-heavy index, added 2.77%.
Prior to today's trading, shares of the drugmaker had gained 0.55% over the past month. This has outpaced the Medical sector's loss of 4.27% and the S&P 500's loss of 5.06% in that time.
Investors will be hoping for strength from Sanofi as it approaches its next earnings release. On that day, Sanofi is projected to report earnings of $1.10 per share, which would represent year-over-year growth of 0.92%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.27 billion, up 3.85% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.40 per share and revenue of $48.91 billion, which would represent changes of +1.15% and +8.3%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Sanofi. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.23% lower within the past month. Sanofi is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Sanofi's current valuation metrics, including its Forward P/E ratio of 10.87. This represents a discount compared to its industry's average Forward P/E of 13.95.
Also, we should mention that SNY has a PEG ratio of 1.47. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. SNY's industry had an average PEG ratio of 1.6 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 107, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Sanofi (SNY) Stock Moves -0.61%: What You Should Know
In the latest trading session, Sanofi (SNY - Free Report) closed at $47.57, marking a -0.61% move from the previous day. This move was narrower than the S&P 500's daily loss of 0.7%. Meanwhile, the Dow lost 0.87%, and the Nasdaq, a tech-heavy index, added 2.77%.
Prior to today's trading, shares of the drugmaker had gained 0.55% over the past month. This has outpaced the Medical sector's loss of 4.27% and the S&P 500's loss of 5.06% in that time.
Investors will be hoping for strength from Sanofi as it approaches its next earnings release. On that day, Sanofi is projected to report earnings of $1.10 per share, which would represent year-over-year growth of 0.92%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $11.27 billion, up 3.85% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $4.40 per share and revenue of $48.91 billion, which would represent changes of +1.15% and +8.3%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Sanofi. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.23% lower within the past month. Sanofi is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note Sanofi's current valuation metrics, including its Forward P/E ratio of 10.87. This represents a discount compared to its industry's average Forward P/E of 13.95.
Also, we should mention that SNY has a PEG ratio of 1.47. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. SNY's industry had an average PEG ratio of 1.6 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 107, putting it in the top 43% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.